Skip to main content

OmniScience Capital launches the Omni Bharat Amrit Kaal

                      Bharat@100, in 2047, could be a $32 trillion economy

On the occasion of the Azadi Ka Amrit Mahotsav of Bharat, OmniScience Capital, a Global Investment Management firm driven by its proprietary Scientific Investing philosophy, has launched a new investment strategy - the Omni Bharat Amrit Kaal, a portfolio of key growth vectors which are being promoted and initiated in the Union Budget to grow over the next 25 years. The Omni Bharat Amrit Kaal portfolio, currently, provides exposure to six growth vectors, such as Financing of Investments, AtmaNirbhar Defence, GatiShakti, Clean Technology, Inclusive Development, and Productivity Enhancement. AtmaNirbhar Defence and Clean Technology are part of the budget as well under the four main heads.

Dr Vikas Gupta, CEO and Chief Investment Strategist, OmniScience Capital says “Our calculations suggest that Bharat@100, in 2047, could be a $32 trillion economy. In a more optimistic scenario, it could even be a $51 trillion economy and in a conservative scenario it could be a $25 trillion economy. Hence, the Omni Bharat Amrit Kaal investment portfolio in the best case scenario can prove to be a great wealth multiplier in this long run where India aims becoming a fully developed nation”

 The Omni Bharat Amrit Kaal portfolio remains consistent with our Scientific Investing Framework. The difference from other strategies, is that in the other strategies the growth vectors are identified based on a bottom-up analysis of the high growth, but below-the-radar companies where the management has an articulated strategy for capitalizing on the growth vectors are missed out on. In the Omni Bharat Amrit Kaal portfolio, the growth vectors have been articulated by the Government of India with a huge commitment to these growth vectors for the next 25 years. Thus, the investment risk from the growth vectors not continuing is low.

The financial ratios, too, show that this portfolio is composed of high-quality companies with strong balance sheets, persistent competitive advantages and are available at a significant discount to their intrinsic values. Of course, some of the growth vectors will be accelerated over the next 3-10 years while others will grow steadily over the next 25 years. PM GatiShakti and Financing of Investments are likely to be the accelerated growth vectors and Inclusive Development and Productivity Enhancement are likely to last for a substantial portion of the next 25 years.

The Amrit Kaal Budget 2022 provides for infrastructure development through PM GatiShakti, increasing buying power of the citizens and creating a developmental ecosystem for rural and bottom of the pyramid Bharatiyas in a broad-based manner through Inclusive DevelopmentProductivity Enhancement through a digital ecosystem, enhanced infrastructure and reforms, and capital availability through Financing of Investments. When all these four engines are firing in a synchronized manner the country is likely to accelerate into the group of Developed Countries during the Amrit Kaal of next 25 years” Mr Gupta added

For reference, the US today is a $25 trillion economy and China is a $17 trillion economy. The per capita income of Bharat@100 would be around $20,000 in the base case, $32,000 in the optimistic case and $16,000 in the conservative case. For reference, Greece, Hungary, and Poland have a per capita of around $20,000 today. Spain, Taiwan, and South Korea have a per capita of around $30,000-$36,000, and China has a per capita of $12,000 and Chile $16,000.”

About OmniScience Capital

OmniScience Capital is a Global Investment Management firm focused on global equity investments empowered by its proprietary Scientific Investing philosophy.

OmniScience Capital is founded by Dr. Vikas Gupta (B.Tech IIT Bombay, MS and Doctotrate, Columbia University, NY) with a view to provide a scientific approach to equity investments and to pioneer global investing for Indian investors, via SuperNormal Portfolios. His deep immersive research and analysis of more than 100 years of investment management history  combined with experience of investing over multiple cycles across different markets led him to the insight that "Chasing Alpha leads to Risks and Chasing Safety leads to Alpha". This insight is the crux of Scientific Investing, which is the proprietary investment approach followed at OmniScience Capital. The motto is: Enhance Safety, Enhance Growth, Enhance Returns.


OmniScience Capital is proponents of investing in US and other global developed markets as part of an investor’s long term asset allocation strategy. While the Indian investor is misinformed that investing in India has yielded and will yield better returns than the US, because India is an emerging country; the truth is that the S&P500 has outperformed the Nifty50 in the short run and the long run. The reason is not only the depreciation of the INR, but also that certain opportunities exist in the US, that do not exist in India; for example transformative technology firms working on Metaverse, Industry 4.0, AI, IoT, Cloud, 5G products, platforms and infrastructure

Comments

Popular posts from this blog

Smallcase Platform: 2025 Wealth Creation Strategies to Achieve Your Investment Goals

  By Dr. Vikas Gupta, CEO and Chief Investment Strategist, OmniScience Capital In the intricate world of finance, wealth creation is a universal aspiration among investors, though few truly attain it. With a plethora of investment products, philosophies, and strategies available, the challenge is identifying an approach that not only offers returns but also minimizes risk. At OmniScience Capital, we believe the key to successful wealth creation lies in a scientific and disciplined investment strategy. Our unique offerings, rooted in the principles of Scientific Investing, are designed to help you achieve your financial goals with confidence. Pioneering Global Investing and Outperforming on Smallcase Platform OmniScience Capital, a global investment management firm specializing in global and Indian equities, is a pioneer in global investing and growth vectors such as Defense and Digital Transformation. Our strategies have consistently identified and capitalized on growth vectors tha...

Country Delight Launches NMR-Tested Honey: The Gold Standard of Purity

  Country Delight continues strengthening its promise of delivering the best purity and quality by launching 100% Pure Farm Honey (NMR Tested) Country Delight, a trusted name in premium and natural essentials, has announced the launch of 100% Pure Farm Honey (NMR Tested). Country Delight’s Farm Honey is Nuclear Magnetic Resonance (NMR) tested by a certified lab in Germany, making it one of the most authentic and reliable kitchen ingredients available to Indian homes. It also undergoes rigorous testing on 36 quality parameters as per FSSAI standards, including physicochemical, antibiotic and microbial, to rule out the presence of added sugars. Honey is not just a natural sweetener; it is increasingly valued for its functional benefits. With Country Delight's NMR-tested honey, consumers can enjoy a product that supports wellness through its natural composition, which is rich in antioxidants and phytonutrients and offers advantages over refined sugars.  Adulteration with cheaper ...

Prachay Capital’s Public Issue of Secured NCDs Fully Subscribed at 113.36%

Prachay Capital Limited, an RBI-registered Non-Banking Financial Company – Investment and Credit Company (NBFC-ICC), has successfully closed its public issue of Secured, Rated, Redeemable Non-Convertible Debentures (NCDs) at 113.36% subscription, according to exchange data. The issue, which opened on February 28, 2025, on the Bombay Stock Exchange (BSE), aimed to raise Rs 50 crore (excluding the greenshoe option) and closed on March 13, 2025. With a BSE listing, this issue was open for subscription to retail investors, high-net-worth individuals (HNIs), institutional investors, and corporates. The maiden NCDs issue is scheduled to list on 24 March 2025.  Rated BBB-/Stable by CRISIL, these NCDs offer investors a 13% per annum return with monthly interest payouts, making them an attractive fixed-income opportunity. The proceeds will be deployed as per the company’s stated fund allocation plan. Fund Utilization: Minimum 75% for the purpose of onward lending, investments in current and...